Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
Seiichi Okabe(Tokyo Medical University), Kazuma Ohyashiki(Tokyo Medical University)
Cited by 9
Related Papers
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
|Cancer Cell International|2013|21